A landmark study has raised the prospect of Britain pioneering the use of human embryo gene editing to eradicate inherited diseases.
Scientists in the US reached a new milestone by successfully altering DNA in defective embryos so they were no longer programmed to develop heart failure.
It is the first time the powerful gene-editing tool Crispr-Cas9 has been used to fix a mutation responsible for a common inherited disease.
The highly controversial technique is still at an early experimental stage and there is no question of any attempt being made to create babies with the genetic modification, which would be illegal both in the US and the UK.
But a leading member of the team has hinted that first steps towards bringing the treatment to patients could take place in the UK under the direction of the fertility regulator the Human Fertilisation and Embryology Authority (HFEA).
Dr Shoukhrat Mitalipov, from Oregon Health and Science University (OHSU) in Portland, said in a telephone briefing with journalists: "Maybe .. (the) HFEA might take a lead on this, but I'm quite sure before these clinical trials can go on they have to go through, I believe, Parliament to change a law. So there is still a long road ahead, particularly if you want to do it in a regulatory way."
US regulatory barriers to such research are so high they could be insurmountable. In the US, taxpayer funds cannot pay for research that destroys human embryos. And Congress has banned the US Food and Drug Administration (FDA) from even considering the possibility of human clinical trials involving embryos with edited inherited genes.
More liberal Britain has already blazed a trail by becoming the first country officially to sanction mitochondrial replacement therapy (MRT), seen by some as opening the door to "designer babies".
The treatment replaces faulty inherited DNA in the mitochondria, tiny rod-like bodies in cells that supply energy, to prevent devastating diseases.
However the new research reported in the journal Nature goes much further by modifying the nuclear DNA at the heart of the cell that influences personal characteristics such as height, facial appearance, eye colour and intelligence.
Leaked information has already led to widespread speculation about the study. The published paper explains how Crispr-Cas9 was used to repair human embryos blighted by a single copy of a mutant gene, MYBPC3, that causes hypertrophic cardiomyopathy, a type of heart failure.
Using standard IVF techniques, the scientists first fertilised donor eggs with sperm containing the defective gene. At the time of fertilisation, they applied the gene-editing tool that acts like a pair of precisely targeted genetic scissors.
Once the defective elements of the gene had been snipped away, the embryo's own cellular repair systems replaced them with healthy versions.
Nature stepped in at this point in a clever way, by using the egg donor's properly functioning MYBPC3 gene as a template on which to base the repair.
Forty two out of 58 embryos (72.4%) were correctly fixed so that they no longer carried the heart failure mutation, which normally has a 50% chance of being passed on.
None of the embryos were permitted to develop beyond the blastocyst stage five days after conception. Had they produced offspring, those with the repair would no longer be at risk of developing hypertrophic cardiomyopathy or passing the defective gene onto to their own children.
Dr Mitalipov said: "Every generation on would carry this repair because we've removed the disease-causing gene variant from that family's lineage.
"By using this technique, it's possible to reduce the burden of this heritable disease on the family and eventually the human population."
Hypertrophic cardiomyopathy affects around one in 500 people and can result in sudden death.
It occurs when the walls of the heart become thickened and stiff, making it more difficult for the organ to pump blood around the body.
Co-author Professor Sanjiv Kaul, from OHSU's School of Medicine, said: "Although it affects men and women of all ages, it's a common cause of sudden cardiac arrest in young people and it could be eliminated in one generation in a particular family."
The disease is one of more than 10,000 heritable conditions caused by an error in a single gene.
Dr Mitalipov said the same technique could be used to repair the faults responsible for any of these disorders. He also wanted to explore the possibility of targeting cancer mutations, such as the BRCA1 and 2 gene defects that cause inherited breast cancer.
Before clinical trials could be considered, the technique would have to be made more efficient and further checks would have to be made to ensure its safety, he said.
"I'm quite sure there are tools we could use to improve the repair to 90 - 100% efficiency and then we will be ready to move to clinical trials," said Dr Mitalipov. He was unable to say how long this might take.
The scientists found no evidence of "off-target" changes to DNA in the embryos caused by the gene-editing scissors cutting the wrong areas.
Nor was there any evidence of "mosaicism" which could cause the embryos to end up with a mixture of repaired and defective cells.
Dr David King, director of the Human Genetics Alert, which opposes all tampering with the human genome, said: "If irresponsible scientists are not stopped, the world may soon be presented with a fait accompli of the first GM baby.
"We call on governments and international organisations to wake up and pass an immediate global ban on creating cloned or GM babies, before it is too late."
An HFEA spokesman said: "UK researchers can apply for a licence to edit human embryos in research, but offering it as a treatment is currently illegal.
"Introducing new, controversial techniques is not just about developing the science - gene editing would need to offer new options to couples at risk of having a child with a genetic disease, beyond current treatments like embryo testing.
"Our experience of introducing mitochondrial donation in the UK shows that high-quality public discussion about the ethics of new treatments, expert scientific advice and a robust regulatory system are crucial when considering new treatments of this kind."